N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Sponsor: Sanofi • ClinicalTrials.gov ID: NCT07170917

Registry updated: 2026-10-14
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period. The randomized treatment duration will be up to approximately 152 weeks

Interventions

  • Brivekimig (Drug)
    * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection
  • Placebo (Drug)
    * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection

Eligibility criteria

Inclusion Criteria: * Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline * Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), one of which must be Hurley Stage II or Hurley Stage III. * Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics, demonstrated intolerance to antibiotics, or has a contraindication to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history. * Participants must be either biologic-naive or biologic-experienced. * Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline visit. * Participant must have a draining tunnel count of ≤20 at the Baseline visit. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS * History of recurrent or recent serious infection * Known history of significant immunosuppression * History of solid organ transplant or stem cell transplant * History of splenectomy * History of moderate to severe congestive heart failure. * History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease * Participants with a history of malignancy or lymphoproliferative disease other than adequately treated or nonmetastatic squamous cell carcinoma of the skin that was excised and completely cured or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured * History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol * Active suicidality and therefore significant suicide risk, as judged by the Investigator * A history of an Adverse Event (AE) attributed to or related to anti-TNF therapy (examples include, but are not limited, to serum sickness or anaphylaxis) for an HS or non-HS indication that would contraindicate readministration of an anti-TNF class therapy * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study * History (within last 2 years prior to Baseline visit) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Conditions

Hidradenitis Suppurativa

Locations

  • Medical Dermatology Specialists- Site Number : 8400019 — Phoenix, Arizona, United States
  • Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014 — Scottsdale, Arizona, United States
  • Northridge Clinical Trials - Northridge- Site Number : 8400005 — Northridge, California, United States
  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8400001 — Fort Myers, Florida, United States
  • FXM Clinical Research - Miami- Site Number : 8400017 — Miami, Florida, United States
  • FXM Clinical Research - Miramar- Site Number : 8400004 — Miramar, Florida, United States
  • Advanced Medical Research - Atlanta- Site Number : 8400011 — Atlanta, Georgia, United States
  • Georgia Skin & Cancer Clinic- Site Number : 8400009 — Savannah, Georgia, United States
  • The Iowa Clinic West Des Moines Campus- Site Number : 8400007 — West Des Moines, Iowa, United States
  • Louisiana Dermatology Associates- Site Number : 8400006 — Baton Rouge, Louisiana, United States
  • Washington University- Site Number : 8400010 — St Louis, Missouri, United States
  • JDR Dermatology Research- Site Number : 8400012 — Las Vegas, Nevada, United States
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400021 — New York, New York, United States
  • University of North Carolina at Chapel Hill- Site Number : 8400025 — Chapel Hill, North Carolina, United States
  • Clinical Partners- Site Number : 8400002 — Johnston, Rhode Island, United States
  • AMR Clinical South Strand, South Carolina- Site Number : 8400018 — Myrtle Beach, South Carolina, United States
  • Ut Southwestern Medical Center, Department Of Dermatology- Site Number : 8400022 — Dallas, Texas, United States
  • Investigational Site Number : 0360003 — Liverpool, New South Wales, Australia
  • Investigational Site Number : 0360002 — Melbourne, Victoria, Australia
  • Investigational Site Number : 1240008 — Edmonton, Alberta, Canada
  • Investigational Site Number : 1240007 — Sherwood Park, Alberta, Canada
  • Investigational Site Number : 1240003 — Kelowna, British Columbia, Canada
  • Investigational Site Number : 1240001 — Hamilton, Ontario, Canada
  • Investigational Site Number : 1240009 — Toronto, Ontario, Canada
  • Investigational Site Number : 1240005 — Québec, Quebec, Canada
  • Investigational Site Number : 1520004 — Talcahuano, Biobio, Chile
  • Investigational Site Number : 1520003 — Santiago, Reg Metropolitana de Santiago, Chile
  • Investigational Site Number : 1520002 — Santiago, Reg Metropolitana de Santiago, Chile
  • Investigational Site Number : 1520001 — Santiago, Reg Metropolitana de Santiago, Chile
  • Investigational Site Number : 1520005 — Santiago, Reg Metropolitana de Santiago, Chile
  • Investigational Site Number : 1560002 — Chengdu, China
  • Investigational Site Number : 1560001 — Guangzhou, China
  • Investigational Site Number : 1560004 — Shanghai, China
  • Investigational Site Number : 1560005 — Ürümqi, China
  • Investigational Site Number : 2030002 — Ostrava, Czechia
  • Investigational Site Number : 2030003 — Ostrava, Czechia
  • Investigational Site Number : 2030001 — Prague, Czechia
  • Investigational Site Number : 2030004 — Prague, Czechia
  • Investigational Site Number : 2500001 — Antony, France
  • Investigational Site Number : 2500004 — Bezannes, France
  • Investigational Site Number : 2500003 — Bordeaux, France
  • Investigational Site Number : 2500002 — Lyon, France
  • Investigational Site Number : 2500006 — Saint-Priest-en-Jarez, France
  • Investigational Site Number : 2500007 — Toulouse, France
  • Investigational Site Number : 2760002 — Bochum, Germany
  • Investigational Site Number : 2760008 — Bramsche, Germany
  • Investigational Site Number : 2760003 — Frankfurt, Germany
  • Investigational Site Number : 2760005 — Kiel, Germany
  • Investigational Site Number : 2760004 — Mainz, Germany
  • Investigational Site Number : 2760001 — Münster, Germany
  • Investigational Site Number : 2760006 — Würzburg, Germany
  • Investigational Site Number : 3000002 — Athens, Greece
  • Investigational Site Number : 3000001 — Athens, Greece
  • Investigational Site Number : 3000005 — Athens, Greece
  • Investigational Site Number : 3000004 — Thessaloniki, Greece
  • Investigational Site Number : 3480001 — Debrecen, Hungary
  • Investigational Site Number : 3480003 — Pécs, Hungary
  • Investigational Site Number : 3480004 — Székesfehérvár, Hungary
  • Investigational Site Number : 3760003 — Haifa, Israel
  • Investigational Site Number : 3760002 — Jerusalem, Israel
  • Investigational Site Number : 3760001 — Tel Aviv, Israel
  • Investigational Site Number : 3800004 — Rome, Lazio, Italy
  • Investigational Site Number : 3800002 — Milan, Milano, Italy
  • Investigational Site Number : 3800005 — Rozzano, Milano, Italy
  • Investigational Site Number : 3800006 — Rome, Roma, Italy
  • Investigational Site Number : 3800001 — Catania, Italy
  • Investigational Site Number : 3920003 — Nishinomiya, Hyōgo, Japan
  • Investigational Site Number : 3920002 — Nishihara, Okinawa, Japan
  • Investigational Site Number : 3920001 — Tokyo, Japan
  • Investigational Site Number : 5280002 — Groningen, Netherlands
  • Investigational Site Number : 6160004 — Wroclaw, Lower Silesian Voivodeship, Poland
  • Investigational Site Number : 6160001 — Wroclaw, Lower Silesian Voivodeship, Poland
  • Investigational Site Number : 6160003 — Lodz, Lódzkie, Poland
  • Investigational Site Number : 6160002 — Warsaw, Masovian Voivodeship, Poland
  • Grupo Dermatologico de Carolina- Site Number : 8400023 — Carolina, Puerto Rico
  • Investigational Site Number : 7240006 — Santiago de Compostela, A Coruña [La Coruña], Spain
  • Investigational Site Number : 7240004 — Cadiz, Andalusia, Spain
  • Investigational Site Number : 7240003 — Las Palmas de Gran Canaria, Las Palmas, Spain
  • Investigational Site Number : 7240001 — Madrid, Madrid, Comunidad de, Spain
  • Investigational Site Number : 7240002 — Manises, Valencia, Spain
  • Investigational Site Number : 7240007 — Granada, Spain
  • Investigational Site Number : 7240005 — Madrid, Spain
  • Investigational Site Number : 7840001 — Abu Dhabi, United Arab Emirates
  • Investigational Site Number : 8260008 — London, England, United Kingdom
  • Investigational Site Number : 8260006 — Leeds, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record